Evaxion welcomes Per Norlén as new CEO.
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd.
Dr. Norlén is a board-certified physician and associate professor with more than 20 years in the biotech sector, of which the last decade has been in executive leadership roles. He brings a wealth of experience from being CEO of listed drug development companies. He has a proven business development track record, including major out-licensing deals with biotech and Pharma.
“Evaxion has emerged from being an under-the-radar start-up to becoming a clinical stage biotech company leading the development of tailored cancer immunotherapies, individually designed for each patient. I am convinced that Evaxion is on to something extremely important that holds the potential to become a game-changer for patients with metastatic cancer. During my previous career, I have always dreamt of making the perfect drug, and I feel enormously privileged to now be part of a team that I believe is doing just that. This is clearly within reach with a newly initiated phase 2b trial in melanoma that will hopefully confirm the very promising phase 1 efficacy signals,” says Per Norlén, CEO at Evaxion.
Chairman of the board, Marianne Soegaard, says the new hire signals the next stage for the biotech company:
“With Per at the steering wheel, we expect to bring our promising clinical and preclinical results to the next level. Evaxion is a profoundly innovative and talented company working tirelessly to save patients' lives. Per Norlén is joining the company as an experienced leader bringing the necessary expertise and competences to bring Evaxion from an innovative early stage to the next level. I look forward to having Per on board to help realize the vast potential from our clinical trials and create personalized therapies for cancer patients and patients suffering from other critical diseases.”
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. With our proprietary and scalable AI technology, we decode the human immune system to discover and develop novel immunotherapies for patients suffering from cancer or bacterial and viral infections. Evaxion has a broad pipeline of novel product candidates, including three personalized cancer immunotherapies. We are located in Hørsholm, Denmark, and currently have 70 employees.
For more information from Dr. Per Norlén, please contact:
VP, Communications and Public Relations
Katrine Hertz Mortensen
Phone: +45 30 10 02 03
This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks related to the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product supply and manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and the emergence and prevalence of COVID-19 variants, such as Delta and Omicron, and specific related variants such as the Omicron BA.4 and BA.5 variants, risks associated with the hostilities between Ukraine and Russia and other risks and uncertainties affecting the Company’s business operations and financial condition.
Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 31, 2022 and the Company’s current and future reports filed with, or furnished to the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nr. 4 2024 Indkaldelse til generalforsamling21.2.2024 09:00:48 CET | pressemeddelelse
Solar A/S afholder ordinær generalforsamling fredag den 15. marts 2024 kl. 11.00 på adressen Industrivej Vest 43, 6600 Vejen. Generalforsamlingen transmitteres til navnenoterede aktionærer via video-webcast på www.solar.eu. Dagsorden for generalforsamlingen er: 1. Bestyrelsens beretning om selskabets virksomhed i det forløbne regnskabsår. 2. Forelæggelse og godkendelse af årsrapport med revideret årsregnskab Bestyrelsen foreslår, at årsrapporten for 2023 godkendes. 3. Beslutning om anvendelse af overskud i henhold til den godkendte årsrapport Bestyrelsen foreslår dernæst, at der udloddes DKK 219 mio. i udbytte for regnskabsåret 2023, svarende til DKK 30,00 pr. aktie á DKK 100. 4. Vejledende afstemning om godkendelse af vederlagsrapport Vejledende afstemning om den af bestyrelsen udarbejdede vederlagsrapport om aflønning af medlemmerne af bestyrelsen og direktionen i 2023. 5. Godkendelse af bestyrelsens vederlag for det igangværende regnskabsår Bestyrelsen foreslår, at det faste bestyre
No. 4 2024 Notice of general meeting21.2.2024 09:00:48 CET | Press release
The Annual General Meeting of Solar A/S will be held on Friday, 15 March 2024, at 11.00 am, at the address Industrivej Vest 43, 6600 Vejen, Denmark. The general meeting will be broadcast by video webcast at www.solar.eu to shareholders on record in the company’s register of shareholders. The agenda of the general meeting is as follows: 1. The Board of Directors’ report on the company’s activities during the past financial year. 2. Presentation and approval of the annual report with audited financial statements. The Board of Directors proposes that the 2023 annual report be approved. 3. Resolution on the allocation of profits in accordance with the approved annual report. The Board of Directors also proposes that DKK 219m be distributed as dividend for the 2023 financial year, corresponding to DKK 30.00 for each share of DKK 100. 4. Indicative vote on the remuneration report. Indicative vote on the remuneration report prepared by the Board of Directors concerning remuneration of members
Kalmar’s electric and hybrid straddle carriers to play role in cutting emissions at ECT Delta terminal in Rotterdam21.2.2024 09:00:00 CET | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 21 FEBRUARY 2024 AT 10 (EET) Kalmar, part of Cargotec, has concluded an agreement to supply Hutchison Ports ECT Rotterdam with two fully electric and eight hybrid straddle carriers for its ECT Delta terminal. The significant order was booked in Cargotec's 2024 Q1 order intake, with delivery expected to be completed during Q4 2024. Hutchison Ports ECT Rotterdam (ECT) operates two container terminals both located on the North Sea coast of Rotterdam and capable of handling the latest generation of ultra-large container vessels without any restrictions. The ECT Delta uses its fleet of straddle carriers for loading and unloading trucks on the land side. The terminal already operates a number of Kalmar straddle carriers. The new straddle carriers are part of a fleet renewal programme that will support the goal of ECT to achieve emission-free operations at its ECT Delta and ECT Euromax terminals by 2035. ECT will be piloting two different battery technolog
PolyPlank AB: Bokslutskommuniké 202321.2.2024 09:00:00 CET | Pressemelding
Vd har ordet PolyPlank har de senaste åren gjort kraftiga satsningar för att få till ett rejält trendbrott för företaget. Vi fortsätter nu med satsningar, bl.a. stärker vi upp på säljsidan med en person för att hitta alternativa marknadskanaler och marknader för våra produkter samtidigt som kostnadssidan genomgått ett ”stålbad”. Kostymen är nu slimmad. Vi har p.g.a/tack vare de senaste årens kriser anpassat och förändrat PolyPlank för att även klara krisår och jag är övertygad om att vi kommer att få ”skörda” det vi ”sått” och lagt grund för. PolyPlank är nu välrustat för både krisår som ”vanliga” år (om nu såna finns). 22 sept 2022 pressmeddelade vi om 35 st Miljöhus för 4,4 MSEK till Tingsrydbostäder AB. Denna order har legat på is sen dess men nu drar det rejält igång och vi räknar med att börja leverera dessa under resten av året med start i april-maj 2024. 19 dec 2023 Pressmeddelade vi om en order på 2,2 MSEK till Peab, ett bullerplank till Rälla. Vi har nu startat med grundläggni
SUMMONS TO ROBIT PLC’S ANNUAL GENERAL MEETING21.2.2024 09:00:00 CET | Press release
ROBIT PLC STOCK EXCHANGE RELEASE 21 FEBRUARY 2024 AT 10.00 EET SUMMONS TO ROBIT PLC’S ANNUAL GENERAL MEETING The shareholders of Robit Plc are hereby invited to the Annual General Meeting to be held on Wednesday, 3 April 2024 from 14.00 EET onwards at Tampere Hall, address Yliopistonkatu 55, 33100, Tampere, Finland. The reception of registered participants and the distribution of ballots will commence at 13.30 EET. A. Matters on the agenda of the General Meeting The following matters will be discussed at the General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording attendance at the meeting and adoption of the list of votes 6. Presentation of the financial statements and consolidated financial statements, the annual report and the auditor’s report for the year 2023 Presentation of the CEO’s review. Robit Plc’s financial statement